Medlab owns and runs an Office of the Gene Technology Regulator (OGTR) certified PC2 Biologic facility in NSW, Australia.
This is the primary site for Medlab/InMed Technologies research projects.
Presently we are involved in early phase drug discovery in 5 key areas:
- Chronic Kidney Disease
- Miild to moderate Depression
- Anti-aging/muscular and skeletal health
- Non opioid pain management
Medlab has multiple patents pending on our products:
Provisional Patent – Biologics/Cannabinoids
A new composition for the treatment of phrophylaxis of pain with secondary effects for the treatment of nausea and bulimia.
Provisional Patent – Biologics/Chronic Kidney Disease
A new composition for the prophylactic treatment of kidney disease and/or improving kidney function.
Provisional Patent – Biologics/Depression
A new composition for the treatment or prevention of mild to moderate depression, anxiety or a depressive or anxiety disorder.
Provisional Patent – Biologics/Muscular/Skeletal Ageing
A new composition for the treatment or prevention of muscle degeneration associated with age-related or injury-related muscle weakness or atrophy.
Provisional Patent – Biologics/Obesity
A new composition for the treatment of metabolic syndrome and obesity.
Provisional Patent – ImmunBiotic
A new composition for heightening the innate immune system.
Provisional Patent – NRGBiotic
A new composition for stimulating mitochondrial function.
Provisional Patent – AscorBiotic
A new composition for the delivery and uptake of vitamin C in humans.